Search Results

We also touched on how COVID-19 affected her Ph.D. work.

limitations in structural integrity and immunogenicity. mRNA technology, demonstrated in the success of COVID -19 vaccines, is emerging as a promising method for antibody discovery.

From struggling to grip mice in early animal studies to thesis delays during COVID-19, Serafini's journey

Pandemic Journey and Global Challenges Yamina and Arthur discussed Arthur's experiences during the Covid -19 pandemic, his journey as a research fellow in Australia, and his transition to the role of Dean. personal health struggles, the growth of his university, and the faculty's successful response to the Covid

Pandemic Journey and Global Challenges Yamina and Arthur discussed Arthur's experiences during the Covid -19 pandemic, his journey as a research fellow in Australia, and his transition to the role of Dean. personal health struggles, the growth of his university, and the faculty's successful response to the Covid

Both agreed on the importance of adaptability, as unexpected situations like the Covid-19 pandemic can

Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling

Silvio Gutkind sheds light on his work and life since the beginning of COVID restrictions. Silvio Gutkind highlights how his past experience proves useful in current COVID times and potential

GPCR research, developing biosensors for G protein activity, networking, mentorship, PhD resilience, COVID -19 challenges, and his aspiration to transition into biotechnology investment opportunities. Next Call for GPCR Papers Special Issue on Adhesion GPCRs GPCR Events, Meetings, and Webinars March 19

Paul thinks broadly about science and has been actively publishing papers about his ideas on how COVID

envisions using these tools to detect GPCR autoantibodies , which are implicated in conditions like long COVID

Podcast Episodes 2025-12-17 2025-11-05 2025-09-02 2025-07-22 2025-05-27 2025-12-03 2025-10-22 2025-08-19 2025-07-08 2025-05-13 2025-11-19 2025-09-22 2025-08-05 2025-06-11 2025-04-29 1 2 3 4 5 1 ... 1 2 3 4

#gpcr #drgpcr Published on February 19, 2025 Category Dr.

2C-persistent-endosomal-signaling-and-paradoxical-regulation-of-agonist-pharmacology #gpcr#drgpcr Published on May 19

Lefkowitz , 2012 Nobel Laureate in Chemistry. 2nd Annual Summit Sep 13–19, 2021 — The 2nd Dr. First Symposium May 19, 2023 — Hosted the inaugural Dr.

| Sept 9, 2025 🔥 Watch course | Sept 2, 2025 🔥 Watch course | Aug 26, 2025 🔥 Watch course | Aug 19

DrGPCR #FluorescentLigands #GPCRdrugDiscovery #ScientificLeadership #BiotechInnovation Published on June 19

shorter transcripts starting from alternative exons at the intron 17/exon 18 boundary with new or exon 19 The cleaved BAI1 isoform has a 19 amino acid extracellular stalk that can serve as a receptor agonist

Fiona Marshall,(http://www.drgpcr.com/episode-19-from-a-lecture-on-adrenaline-function-to-becoming-a-successful-industry-leader

Each party shall bear one-half of the arbitration fees and costs. 19.

It's easy. 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Call for GPCR Papers NEW Special Issue on Adhesion GPCRs GPCR Events, Meetings, and Webinars March 19

stability-activity tradeoffs, crystallography; started my independent lab at Northwestern University Medical School (1996

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994). Caron at Duke University (1994-1997), where he and his colleagues investigated the role of G protein-coupled Research Chairs since 2001 and was previously a Heart and Stroke Foundation of Canada MacDonald Scholar (1998

was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational

short internship at Genentech Inc. in South San Francisco, he joined the CNRS as a Research Fellow in 1987 In 1999, back in France, Dr.

Premont obtained his B.S. in Biology and Chemistry at the California Institute of Technology in 1985, Biomedical Sciences (Pharmacology) at Mount Sinai School of Medicine (City University of New York) in 1990 and 1992, working with Ravi Iyengar on regulation/desensitization of the liver glucagon receptor and In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert In 1999, obtained an independent faculty position at Duke in Gastroenterology, where he remained until

He began his career in the late 1960s and has been an Investigator of the Howard Hughes Medical Institute since 1976.

first Great Lakes GPCR Retreat was conceived, organized and held in London, Ontario, Canada in October 1999

Premont obtained his B.S. in Biology and Chemistry at the California Institute of Technology in 1985, Biomedical Sciences (Pharmacology) at Mount Sinai School of Medicine (City University of New York) in 1990 and 1992, working with Ravi Iyengar on regulation/desensitization of the liver glucagon receptor and In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert In 1999, obtained an independent faculty position at Duke in Gastroenterology, where he remained until